Sun Pharmaceutical
- All
- News
- Videos
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
Why Trump's 100% Pharma Tariffs May Not Impact Indian Drugmakers Much
US President Donald Trump has said his administration will impose 100 per cent import tariffs on branded or patented pharmaceutical drugs from October 1, unless the pharma companies have or are building their manufacturing units in America.
-
Sun Pharma Flags Revenue Drop Following 'IT Security Incident' in March: Details
Sun Pharmaceutical Industries on Sunday revealed in a filing that the firm would see a revenue drop in a few of its businesses and incur some expenses due to an "IT security incident" in March. The drugmaker's IT systems were affected by a breach of certain file systems and theft of some company and personal data, while a ransomware group has claim...
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Sun Pharma Company Launches COVID-19 Drug Favipiravir In India
Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
-
Sun Pharma Shares Close 4% Lower As Q2 Profit Falls 60%
Shares of Sun Pharmaceutical Industries on Wednesday ended 4 per cent lower after the company reported a 59.19 per cent decline in consolidated net profit
-
Sensex Falls For Third Day, Sun Pharma Slumps 5%
Drugmaker Sun Pharmaceutical Industries' shares slumped as much as 5 per cent to their lowest in over four years
-
Sensex Falls For Third Day; Geopolitical Tensions Spook Investors
Drugmaker Sun Pharmaceutical Industries' shares slumped as much as 5 percent to their lowest in over four years.
-
Telenor Looking to Start Payment Bank in India This Year
Telenor, along with Dilip Shanghvi of Sun Pharmaceuticals and IDFC, had earlier received RBI's approval to set up the payment bank.
-
Sun Pharmaceutical Wins US Approval to Buy Ranbaxy
India's Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission (FTC) said on Friday.
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
Why Trump's 100% Pharma Tariffs May Not Impact Indian Drugmakers Much
US President Donald Trump has said his administration will impose 100 per cent import tariffs on branded or patented pharmaceutical drugs from October 1, unless the pharma companies have or are building their manufacturing units in America.
-
Sun Pharma Flags Revenue Drop Following 'IT Security Incident' in March: Details
Sun Pharmaceutical Industries on Sunday revealed in a filing that the firm would see a revenue drop in a few of its businesses and incur some expenses due to an "IT security incident" in March. The drugmaker's IT systems were affected by a breach of certain file systems and theft of some company and personal data, while a ransomware group has claim...
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Sun Pharma Company Launches COVID-19 Drug Favipiravir In India
Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
-
Sun Pharma Shares Close 4% Lower As Q2 Profit Falls 60%
Shares of Sun Pharmaceutical Industries on Wednesday ended 4 per cent lower after the company reported a 59.19 per cent decline in consolidated net profit
-
Sensex Falls For Third Day, Sun Pharma Slumps 5%
Drugmaker Sun Pharmaceutical Industries' shares slumped as much as 5 per cent to their lowest in over four years
-
Sensex Falls For Third Day; Geopolitical Tensions Spook Investors
Drugmaker Sun Pharmaceutical Industries' shares slumped as much as 5 percent to their lowest in over four years.
-
Telenor Looking to Start Payment Bank in India This Year
Telenor, along with Dilip Shanghvi of Sun Pharmaceuticals and IDFC, had earlier received RBI's approval to set up the payment bank.
-
Sun Pharmaceutical Wins US Approval to Buy Ranbaxy
India's Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission (FTC) said on Friday.
